【摘要】 风湿免疫性疾病是一类影响多系统的慢性疾病，好发于年轻育龄女性。由于疾病性质和妊娠期特殊的生理变化，可能会对妊娠结局产生不利影响，危及母婴健康。近年来，随着免疫学研究的深入，生物靶向治疗逐渐成为妊娠合并风湿免疫性疾病治疗的研究热点。生物制剂通过特异性靶向调节炎症反应中的关键因子，有效缓解疾病症状、减少妊娠并发症，并改善不良妊娠结局。本文系统探讨了生物制剂的结构和药代动力学特点，并根据其作用靶点分类，对不同类别生物制剂在妊娠合并风湿免疫性疾病中的应用现状和未来发展趋势进行了全面综述，旨在为妊娠合并风湿免疫性疾病患者的安全用药和治疗策略提供参考，以期改善母婴健康结局。更多还原

【Abstract】 Rheumatic autoimmune diseases are chronic conditions affecting multiple systems, predominantly occurring in young women of childbearing age. Given the nature of diseases and unique physiological changes during pregnancy, they may adversely impact pregnancy outcomes and endanger maternal and fetal health. In recent years, with the deepening of immunological research, biologically targeted therapy has gradually become a focus of attention in the treatment of rheumatic autoimmune diseases in pregnancy. Biologics effectively alleviate disease symptoms, mitigate pregnancy complications, and improve adverse pregnancy outcomes by targeting pivotal inflammatory factors. The review systematically discusses the structure and pharmacokinetic characteristics of biologics, and comprehensively reviews the current application and future prospects in managing rheumatic autoimmune diseases in pregnancy based on their specific targets. It aims to provide scientific references and guidance on the safe administration of medications and therapeutic strategies for these patients, ultimately enhancing health outcomes for mothers and infants.更多还原